Eprenetapopt is under clinical development by Aprea Therapeutics and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Refractory Acute Myeloid Leukemia have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eprenetapopt’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Eprenetapopt (PRIMA-1MET) is under development for the treatment of urothelial/bladder cancer, gastric cancer, non small cell lung cancer, platinum sensitive high grade serous ovarian cancer (HGSOC), peritoneal cancer, primary fallopian tube cancer and platinum resistant HGSOC, acute myeloid leukemia, frontline and relapsed/refractory TP53 mutant AML, mantle cell lymphoma and relapsed/refractory TP53 mutant chronic lymphoid leukemia. The drug candidate is administered through intravenous route. APR-246 is a quinuclidinone derivative that targets the Wrap53 gene. It was also under development for the treatment of refractory prostate carcinoma and hematologic malignancies like acute lymphoid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia, multiple myeloma, non Hodgkin's lymphoma, Hodgkin's lymphoma, myelofibrosis and metastatic melanoma, small cell lung cancer, breast cancer, adenocarcinoma in gastroesophageal junction cancer, esophageal cancer.
It was also under development for the treatment of non Hodgkin's lymphoma, mantle cell lymphoma, refractory chronic lymphocytic leukemia, relapsed chronic lymphocytic leukemia.
Aprea Therapeutics overview
Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The company offers products that include APR-246 drugs and therapeutics for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and additional hematologic and solid tumor malignancies. It also has pre-clinical research and development to extend its product development. The company has its additional office in Sweden. Aprea Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of Eprenetapopt’s drug-specific PTSR and LoA scores, buy the report here.